Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

Lilly’s other new drugs like Omvoh, Jaypirca and Ebglyss, contributed significantly to top-line growth in 2024, with the trend expected to continue in 2025. Lilly has its share of problems.

such as for the drug Omvoh for Crohn's disease and Ebglyss for atopic dermatitis, further resulted in positive sentiment. These concerted efforts support Eli Lilly's robust performance ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Where will Eli Lilly be in five years ... which made nearly $3.3 billion in sales last year. Omvoh could carve a niche for itself in the Crohn's disease market. Ebglyss should also be able ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Lilly's already holding its own in immunology with Taltz, which made nearly $3.3 billion in sales last year. Omvoh could carve a niche for itself in the Crohn's disease market. Ebglyss should also ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.